Marsi Bionics open a round of €1.5 million to manufacture its exoskeletons

Marsi Bionics calls for private capital. The Spanish company has opened a funding round of $1.8 million (€1.5 million) through the crowdfunding platform Fellow Funders. The company will use the funds to develop its pediatric exoskeletons on an industrial scale and prepare them for the international market. 

Marsi Bionics expects to advance its robotic exoskeletons with variable joint stiffness, which accurately simulate muscles and tendons, to improve the human gait of patients with neuromuscular diseases. The pediatric exoskeleton Atlas 2030 is intended for the treatment of Spinal Muscular Atrophy (SMA). 

If you want to find more details about the new pediatric products developed by the company Marsi Bionics and to read the latest breakthroughs in the biotech sector, download for free our companion app. Born2Invest brings you the most important business news in the world so you can stay on top of the market.

The new product developed by Marsi Bionics could increase life expectancy with 50%

The company will also allocate the amount collected for the incorporation of new professionals in areas such as engineering, information and communication technologies (ICT) and business development. The company has already raised more than $300,000 (€250,000). Marsi Bionics will incorporate new professionals specialized in engineering, ICT and business development Marsi Bionics is a spin off from the Center for Automation and Robotics (CAR), a joint center of the Polytechnic University of Madrid (UPM) and the Spanish National Research Council (Csic). 

It is estimated that continuous therapy with the exoskeleton has a direct impact on health problems caused by SMA and can achieve 50% more life expectancy. The use of this product could be extended to diseases such as cerebral palsy, dystrophies, or chronic neurological damage. It is estimated that these diseases affect more than seventeen million children worldwide. 

The company started its activity in 2013 and has carried out clinical trials in hospitals in Spain and France

At present, Marsi Bionics is carrying out a clinical trial together with Csic and Sanitas in patients affected by stroke, with difficulties in walking, and also plans to enter into other types of pathologies and surgeries. Marsi Bionics is carrying out a clinical trial together with Csic and Sanitas. On the other hand, the company is developing the robotic knee MAK Active Knee, which was recently certified by the Spanish Agency of Medicines and Health Products (Aemps). 

The company pointed out that the use of this product, after knee prosthesis surgery, allows a 66% faster, more stable, effective and painless rehabilitation. Marsi Bionics, founded by Elena García, managed for the first time to exceed $1.2 million (€1 million) in revenue in 2019. The company estimates it will reach, if it also meets the marketing forecast of its exoskeleton for adults, up to $12 million (€10 million) in revenue in 2022.

__

(Featured image by ThisIsEngineering via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.